Effects of Thread Embedding Combined with Guided Surgery on Clinical Efficacy and Immune Function in Immunotherapy for Advanced Gastric Cancer

INTERVENTION: Immunotherapy + Baduanjin group:Baduanjin;Immunotherapy:NA; CONDITION: gastric cancer PRIMARY OUTCOME: Cytokine Inflammation Index;Immunotherapy response rate: Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD).;Assessment scale;Survival analysis: overall survival (OS) and progression‐free survival (PFS) within 2 years.; SECONDARY OUTCOME: Detection of transcription factors in gastric cancer tissue;Serum metabolomics analysis;Assessment of treatment‐related toxicities and adverse reactions; INCLUSION CRITERIA: 1.Age>= 18 years old, gender not limited; 2.Body weight > 45 kg; 3. Patients with advanced gastric malignant tumors, with clear pathological evidence; 4. Have not received systemic treatment before and are planned to receive first‐line chemotherapy combined with immunotherapy; 5.ECOG score: 0‐1, KPS score: 80‐100; 6. Expected survival period >= 6 months; 7.Good compliance, voluntarily participate in this trial and sign the informed consent form.